Skye Bioscience, Common Stock Investor Sentiment

SKYE Stock  USD 2.83  0.28  10.98%   
About 57% of all Skye Bioscience,'s shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Skye Bioscience, Common suggests that some traders are interested. The current market sentiment, together with Skye Bioscience,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Skye Bioscience, Common stock news signals to limit their universe of possible portfolio assets.
  

Skye Bioscience, Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Skye Bioscience, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two weeks ago at gurufocus.com         
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application for TNX-102 SL ...
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
Certain Options of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on ...
Google News at Macroaxis
over three weeks ago at www.macroaxis.com         
Acquisition by Saenger Bradley of 540000 shares of Tonix Pharmaceuticals at 1.22 subject to Rule 16b...
Macroaxis News
over a month ago at investing.com         
Tonix Pharma earnings beat by 2.70, revenue fell short of estimates
Investing News at Macroaxis
few days ago at express.co.uk         
The five most anticipated new cars of 2025, including the controversial new Jaguar
news
over a week ago at aol.com         
Tributes to holidaymaker who died in road accident
news
over a week ago at finance.yahoo.com         
EV maker Lucid asks drivers to Compromise Nothing in first ad campaign
Yahoo News
over two weeks ago at electrek.co         
Lucid CEO hints at EV partnerships with a couple of auto companies
news
over two weeks ago at www.macroaxis.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Macroaxis News
over a month ago at zacks.com         
Marinus Pharmaceuticals Reports Q3 Loss, Misses Revenue Estimates
zacks News
over three months ago at benzinga.com         
Dow Tumbles 950 Points ISM Services PMI Surges In July
benzinga news
over three months ago at businesswire.com         
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic A...
businesswire News
over six months ago at news.google.com         
VBI Vaccines slides on discounted stock and warrants offering - MSN
Google News at Macroaxis
over a year ago at benzinga.com         
TCR2 Therapeutics Insider Trades Send a Signal
benzinga news
over a year ago at globenewswire.com         
TCR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Macroaxis News: globenewswire.com
over a year ago at www.macroaxis.com         
Tcr2 Therapeutics exotic insider transaction detected
Macroaxis News
over a year ago at investing.com         
Tcr2 Therapeutics earnings missed by 0.76, revenue was in line with estimates
Investing News at Macroaxis
over two weeks ago at investing.com         
Disposition of 2635 shares by Jack Anders of Revolution Medicines at 45.4038 subject to Rule 16b-3
Investing News at Macroaxis
over three weeks ago at thelincolnianonline.com         
HC Wainwright Has Positive Forecast for RVMD FY2024 Earnings
news
over three weeks ago at globenewswire.com         
Revolution Medicines Announces Pricing of Upsized 750.0 Million Public Offering of Common Stock and ...
Macroaxis News: globenewswire.com
over three weeks ago at seekingalpha.com         
Revolution Medicines commences public offering of common stock
seekingalpha News
over two weeks ago at zacks.com         
Black Diamond Upgraded to Buy Heres What You Should Know
zacks News
over a week ago at news.google.com         
BDTX stock touches 52-week low at 2.31 amid market challenges - Investing.com
Google News at Macroaxis
over two months ago at thelincolnianonline.com         
Black Diamond Therapeutics, Inc. Short Interest Update
news
over two weeks ago at investing.com         
Disposition of 2635 shares by Jack Anders of Revolution Medicines at 45.4038 subject to Rule 16b-3
Investing News at Macroaxis
over two weeks ago at zacks.com         
Black Diamond Upgraded to Buy Heres What You Should Know
zacks News
over three weeks ago at globenewswire.com         
Revolution Medicines Announces Pricing of Upsized 750.0 Million Public Offering of Common Stock and ...
Macroaxis News: globenewswire.com
over three weeks ago at seekingalpha.com         
Revolution Medicines commences public offering of common stock
seekingalpha News
over a month ago at www.macroaxis.com         
Acquisition by Lynx1 Capital Management Lp of 259998 shares of Passage Bio at 0.5641 subject to Rule...
Macroaxis News
over two months ago at news.google.com         
Passage Bio stock hits 52-week low at 0.57 amid market challenges - Investing.com
Google News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Stoke Therapeutics, Inc. CEO Edward M. Md Kaye Sells 6,786 Shares
news
over three weeks ago at businesswire.com         
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the ...
businesswire News
over a month ago at news.google.com         
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc - GuruFocus.com
Google News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Monte Rosa Therapeutics Shares Down 6 percent Should You Sell?
news
over two weeks ago at finance.yahoo.com         
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and...
Yahoo News
over three weeks ago at zacks.com         
Wall Street Analysts See a 64.09 percent Upside in Monte Rosa Therapeutics Can the Stock Really Move...
zacks News
over a month ago at seekingalpha.com         
Monte Rosa Therapeutics GAAP EPS of -0.29
seekingalpha News
over a month ago at news.google.com         
2 Penny Stocks That Wall Street Predicts Will Soar 306 percent To 1,183 percent In 2025 - Barchart
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
Cabaletta Bios Buy Rating Reaffirmed at HC Wainwright
news
over a month ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition of Cabaletta Bio Inc Shares
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Stu...
Yahoo News
over three weeks ago at investing.com         
Larimar Therapeuticss SWOT analysis nomlabofusp progress lifts stock outlook
Investing News at Macroaxis
over a month ago at gurufocus.com         
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration ...
Gurufocus Stories at Macroaxis
over a month ago at zacks.com         
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
zacks News
over three weeks ago at gurufocus.com         
Disposition of 14892 shares by Romano Gary of Alector at 2.5194 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a month ago at globenewswire.com         
Alector Secures Flexible Credit Facility for Up to 50 Million From Hercules Capital
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Skye Bioscience, that are available to investors today. That information is available publicly through Skye media outlets and privately through word of mouth or via Skye internal channels. However, regardless of the origin, that massive amount of Skye data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Skye Bioscience, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Skye Bioscience, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Skye Bioscience,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Skye Bioscience, alpha.

Skye Bioscience, Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Jenkins Annalisa of 70000 shares of Skye Bioscience, at 5.15 subject to Rule 16b-3
10/28/2024
2
Acquisition by Dhillon Punit of 110000 shares of Skye Bioscience, at 0.0171 subject to Rule 16b-3
11/01/2024
3
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in ...
11/04/2024
4
Skye Bioscience GAAP EPS of -0.10 beats by 0.15
11/07/2024
5
Disposition of 307 shares by Grayson Paul A. of Skye Bioscience, at 5.55 subject to Rule 16b-3
11/15/2024
6
Disposition of 19489 shares by Diep Tuan Tu of Skye Bioscience, at 4.99 subject to Rule 16b-3
11/20/2024
7
Dont Ignore The Insider Selling In Skye Bioscience
11/22/2024
8
Insider Trading
12/09/2024
9
Callum Skye interior revealed First-look inside Ian Callums go-anywhere EV
12/11/2024

Complementary Tools for Skye Stock analysis

When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk